摘要
癌症患者是新型冠状病毒肺炎(COVID‑19)的高风险人群,多国疾病控制预防机构和癌症相关学术团体均建议优先为癌症患者接种COVID‑19疫苗。目前获准紧急使用的COVID‑19疫苗(包括灭活疫苗、信使核糖核酸疫苗、重组腺病毒载体疫苗和重组蛋白亚单位疫苗)均可以用于癌症患者。稳定期患者可以随时接种COVID‑19疫苗,进展期或正在接受抗癌治疗的患者应根据具体情况(治疗方式/癌症类型等)决定疫苗接种时间。癌症患者接种COVID‑19疫苗的益处可能大于风险,但免疫应答率可能低于健康人,尤其是血液系统恶性肿瘤患者。
Patients with cancer are at high risk for coronavirus disease 2019(COVID‑19).Institu‑tions for disease control and prevention and cancer‑related learned societies in many countries recommend prioritizing cancer patients for COVID‑19 vaccines.All the COVID‑19 vaccines currently approved for emer‑gency use,including inactivated vaccines,mRNA vaccines,recombinant adenovirus vector‑based vaccines,and recombinant protein subunit vaccines,can be applied in cancer patients.Cancer patients with stable disease can be vaccinated against COVID‑19 at any time,while patients with advanced‑stage cancer or undergoing anticancer therapy should decide on the timing of vaccination according to the specific situation such as treatment methods and cancer type,etc..The benefits of COVID‑19 vaccination in cancer patients may outweigh the risks,but the immune response rate may be lower in cancer patients,especially in patients with haematological malignancies,than in healthy individuals.
作者
佟志强
邢玥
姜帅
李响
董梅
Tong Zhiqiang;Xing Yue;Jiang Shuai;Li Xiang;Dong Mei(Department of Pharmacy,Harbin Medical University Cancer Hospital,Harbin 150081,China)
出处
《药物不良反应杂志》
CSCD
2021年第7期352-356,共5页
Adverse Drug Reactions Journal
基金
哈尔滨医科大学附属肿瘤医院海燕科研基金(JJZD2019‑03)。
